These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10717564)

  • 1. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
    Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
    Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
    Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
    Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
    Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
    Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
    Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
    Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
    Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
    Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
    Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
    Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
    Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
    Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
    Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
    Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
    Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
    J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum markers in skin melanoma--preliminary study.
    Dumitraşcu G; Constantin C; Manda G; Hristescu S; Mărgaritescu I; Chiriţă D; Neagu M
    Roum Arch Microbiol Immunol; 2009; 68(3):125-35. PubMed ID: 20361532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
    Harpio R; Einarsson R
    Clin Biochem; 2004 Jul; 37(7):512-8. PubMed ID: 15234232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
    Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
    Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
    Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
    Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients.
    Faye RS; Paus E; Maelandsmo GM; Berner A; Høifødt HK; Fodstad Ø; Aamdal S
    Melanoma Res; 2008 Apr; 18(2):134-40. PubMed ID: 18337650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
    Faries MB; Gupta RK; Ye X; Lee C; Yee R; Leopoldo Z; Essner R; Foshag LJ; Elashoff D; Morton DL
    Cancer Invest; 2007 Aug; 25(5):285-93. PubMed ID: 17661202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients.
    Vereecken P; Awada A; Suciu S; Castro G; Morandini R; Litynska A; Lienard D; Ezzedine K; Ghanem G; Heenen M
    Melanoma Res; 2009 Oct; 19(5):316-20. PubMed ID: 19581819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
    Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.